Physician profile
Joel C Everett
NPI 1053327148
$844.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $126 · 2021: $157 · 2022: $452.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $227.54 | 2020-2022 | |
| Abbvie INC. | $99.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.53 | 2020-2022 | |
| Cranial Technologies, INC | $69.54 | 2019-2022 | |
| Kaleo, INC. | $58.00 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $46.92 | 2019-2022 | |
| Corium, LLC | $42.75 | 2022 | |
| Supernus Pharmaceuticals, INC. | $38.99 | 2021-2022 | |
| Sanofi Pasteur INC. | $37.92 | 2019-2020 | |
| Sobi, INC | $31.27 | 2019 | |
| Adlon Therapeutics L.P. | $27.37 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $22.20 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.56 | 2021 | |
| Pfizer INC. | $14.97 | 2021 | |
| Genentech USA, INC. | $11.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.